Hypertrust

Hypertrust is a German healthtech software company focused on orchestration and supply chain management for Advanced Therapy Medicinal Products (ATMP), including personalized cell and gene therapy workflows. The company offers Hypertrust X-Chain, an end-to-end platform that helps pharma, biotech, contract manufacturers, and hospitals coordinate complex treatment journeys with chain-of-identity, chain-of-custody, traceability, and secure data exchange. Originally launched as Hypertrust Patient Data Care, the business was spun out of Camelot Group, became a subsidiary of Elixum in 2023, and later became part of Accenture in 2024. Hypertrust is not a drug developer; it is a commercial platform and services provider supporting operational execution of advanced therapy supply chains.